• Publications
  • Influence
Neuronal and glioma-derived stem cell factor induces angiogenesis within the brain.
TLDR
It is demonstrated that SCF directly activates brain microvascular endothelial cells in vitro and induces a potent angiogenic response in vivo and the SCF/c-Kit pathway plays an important role in tumor- and normal host cell-induced angiogenesis within the brain. Expand
Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.
TLDR
The addition of ixazomib to a regimen of lenalidomide and dexamethasone was associated with significantly longer progression-free survival; the additional toxic effects with this all-oral regimen were limited. Expand
Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1/2
TLDR
The all-oral combination of weekly ixazomib plus lenalidomide and dexamethasone was generally well tolerated and appeared active in newly diagnosed multiple myeloma, and these results support the phase 3 trial development of this combination for multipleMyeloma. Expand
Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed/refractory multiple myeloma patients.
TLDR
In this phase 1 trial, 60 patients with relapsed/refractory multiple myeloma received single-agent ixazomib and among 55 response-evaluable patients, 15% achieved partial response or better (76% stable disease or better). Expand
Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed/refractory multiple myeloma.
TLDR
Nine patients with relapsed and/or refractory multiple myeloma achieved a partial response or better, including 8 of 30 evaluable patients treated at the maximum tolerated dose (MTD) of single-agent, oral ixazomib given weekly for 3 of 4 weeks. Expand
Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with
TLDR
The study met the primary endpoint at the first IA, demonstrating a 35% improvement in PFS with IRd vs Rd, and met the final analysis for PFS, indicating ixazomib may overcome the negative impact of cytogenetic alterations. Expand
Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life
TLDR
The conceptual model developed in this study illustrates the many aspects of multiple myeloma and its treatment and how they can have a negative impact on patients’ HRQL. Expand
Twice-Weekly Oral MLN9708 (Ixazomib Citrate), An Investigational Proteasome Inhibitor, In Combination With Lenalidomide (Len) and Dexamethasone (Dex) In Patients (Pts) With Newly Diagnosed Multiple
TLDR
The results of a phase 1/2 study of twice-weekly oral MLN9708 plus len-dex, conducted in collaboration with the Multiple Myeloma Research Consortium, of safety, tolerability, and the recommended phase 2 dose (RP2D) are reported. Expand
Phase I Trial of the Positron-Emitting Arg-Gly-Asp (RGD) Peptide Radioligand 18F-AH111585 in Breast Cancer Patients
TLDR
18F-AH111585 designed to bind the αvβ3 integrin is safe, metabolically stable, and retained in tumor tissues and detects breast cancer lesions by PET in most anatomic sites. Expand
The Biodistribution and Radiation Dosimetry of the Arg-Gly-Asp Peptide 18F-AH111585 in Healthy Volunteers
TLDR
18F-AH111585 is a safe PET tracer with a dosimetry profile comparable to other common 18F PET tracers, with no serious or drug-related adverse events reported. Expand
...
1
2
3
4
5
...